Median Technologies to Showcase Its Artificial Intelligence Software as a Medical Device for Lung Cancer Screening, eyonis™ LCS, at the European Congress of Radiology
Industry presentation at the AI Theatre: "eyonis™ LCS: Pioneering AI/ML Software as a Medical Device Redefining the Future of Lung Cancer Screening"
Median eyonis™ teams will be at booth #AI-18, AI Exhibition, Expo X1
SOPHIA ANTIPOLIS, France, February 24, 2025--(BUSINESS WIRE)--Regulatory News:
Median Technologies (FR0011049824, ALMDT, PEA/SME eligible, "Median" or "The Company"), a leading developer of eyonis™, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnostics, and a globally leading provider of AI-powered imaging analyses and central imaging services for oncology drug developers, today announced that it will attend the European Congress of Radiology (ECR) 2025 in Vienna, from Feb. 26 to March 2.
The Median eyonis™ team will welcome interested parties at Booth #AI-18, AI Exhibition, Expo X1, from February 26 to March 1 (technical exhibits dates). The Company will share the latest developments for eyonis™ Lung Cancer Screening (LCS) Software as a Medical Device (SaMD).
The Company recently reported that eyonis™ LCS, its AI-powered SaMD for Lung Cancer Screening met the primary endpoint with statistical significance in RELIVE, the second of two successful pivotal studies required for marketing authorizations in US and Europe (ClinicalTrials.gov identifier ID NCT06751576). RELIVE secondary endpoints results will be communicated as soon as all the statistical analyses are finalized.
The protocol and primary endpoints for the two pivotal studies, RELIVE and REALITY, were defined in accordance with discussions held with the FDA. By achieving the primary endpoints in both pivotal studies, eyonis™ LCS has successfully completed the regulatory requirements for clinical validation. Consequently, the regulatory dossiers for obtaining the U.S. 510(k) and European CE marking of eyonis™ LCS will be submitted to the agencies in the second quarter of this year.
"The recently reported pivotal study results suggest eyonis™ LCS may enable broad implementation of LDCT lung cancer screening procedures by improving lung cancer diagnosis accuracy and addressing the bottlenecks of complexity and time required for analyzing LDCT images," said Thomas Bonnefont, COO and CCO of the eyonis™ Business Unit at Median Technologies. "Based on our strong pivotal results, we are now looking towards our filings for marketing authorizations, in both the US and Europe, in Q2 2025, as soon as we finish the analysis. We will report RELIVE secondary endpoints results in the coming weeks. In the interim, we are very pleased to share the eyonis™ LCS pivotal study results already available, and discuss the game changing potential of our Software as a Medical Device with the radiology community at the European Congress of Radiology", Thomas Bonnefont added.
Median's eyonis™ team will present at ECR:
Industry Presentation: "eyonis™ LCS: Pioneering AI/ML Software as a Medical Device Redefining the Future of Lung Cancer Screening" Presenter: Valérie Bourdès, MD, VP Clinical and Medical Affairs, eyonis™ - Median TechnologiesSession AI-IND 3 - AI Lightning Talks 3Wednesday, February 26 - 13:30 – 14:30 CETAI Theatre, ACV Building Level -2
Concurrently, Median's iCRO team will present:
Research Presentation : "Discord Dilemmas in Lung Cancer Clinical Trials: Navigating Reader Variability in Response Assessment" Author: Hubert Beaumont, Lead Scientist, Median TechnologiesResearch Presentation Session: Oncologic ImagingSession: RPS 116 - Staging, metastases and response assessmentWednesday, February 26 – 8:00 – 9:30 CETACV Building, Research Stage 3
About eyonis™ LCS: eyonis™ Lung Cancer Screening (LCS) is an AI/ML-enabled Software as a Medical Device that uses machine learning to analyze imaging data generated with low dose computed tomography (LDCT). eyonis™ LCS aids to diagnose lung cancer at the earliest stages, when it can still be cured in many patients. eyonis™ LCS is the subject of two pivotal studies required for marketing approvals in the U.S. and Europe: REALITY (successfully completed - Clinicaltrials.gov ID: NCT06576232) and RELIVE (primary endpoint successfully achieved, secondary endpoints analysis on-going - Clinicaltrials.gov ID: NCT06751576). Filing applications including these pivotal data are scheduled to be submitted for FDA 510(k) clearance and CE marking in Q2 2025.
About Median Technologies: Pioneering innovative imaging solutions and Software as a Medical Device, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis™, an AI/ML tech-based suite of software as medical devices (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit www.mediantechnologies.com.
Forward-Looking Statements
This press release contains forward-looking statements. These statements are not historical facts. They include projections and estimates as well as the assumptions on which these are based, statements concerning projects, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, or future performance.
These forward-looking statements can often be identified by the words "expects," "anticipates," "believes," "intends," "estimates" or "plans" and any other similar expressions. Although Median's management believes that these forward-looking statements are reasonable, investors are cautioned that forward-looking statements are subject to numerous risks and uncertainties, many of which are difficult to predict and generally beyond the control of Median Technologies, that could cause actual results and events to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements.
All forward-looking statements in this press release are based on information available to Median Technologies as of the date of the press release. Median Technologies does not undertake to update any forward-looking information or statements, subject to applicable regulations, in particular Articles 223-1 et seq. of the General Regulation of the French Autorité des Marchés Financiers.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250224801834/en/
Contacts
MEDIAN TECHNOLOGIES Emmanuelle LeyguesVP, Corporate Marketing & Financial Communications+33 6 10 93 58 88emmanuelle.leygues@mediantechnologies.com
U.S. media & investors Chris MaggosCOHESION BUREAU +41 79 367 6254chris.maggos@cohesionbureau.com
Investors Ghislaine GasparettoSEITOSEI ACTIFIN +33 6 21 10 49 24ghislaine.gasparetto@seitosei-actifin.com
Press Caroline CarmagnolALIZE RP +33 6 64 18 99 59median@alizerp.com
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Indianapolis Star
26 minutes ago
- Indianapolis Star
New to The Street's Featured Client - Roadzen's DrivebuddyAI(TM) Platform Recognized as Key Innovator in InCabin Market Map Report
NEW YORK CITY, NEW YORK / ACCESS Newswire Roadzen Inc. (NASDAQ:RDZN), a global leader at the intersection of artificial intelligence, insurance, and mobility, today announced that its flagship AI-powered platform, DrivebuddyAI™, has been prominently featured in the latest InCabin Market Map Report. The report, released in advance of InCabin USA 2025 in Detroit-the premier event for driver and occupant monitoring technologies-spotlights DrivebuddyAI™ as a key innovator shaping the future of intelligent in-cabin safety and automation. DrivebuddyAI™ is Roadzen's cutting-edge platform combines proprietary AI, computer vision, and driver behavioral analytics to deliver real-time risk driver assessments and coaching to create safer conditions and more efficient outcomes for fleet operators. Its patented technology generates actionable insights for insurers and fleet operators, drawing from diverse environments to create precise risk profiles. Already deployed by several major logistics fleets and certified by ARAI in India, DrivebuddyAI's recognition by InCabin underscores its growing relevance in the global mobility and automotive landscape. 'We are honored that DrivebuddyAI™ is being recognized among the most transformative in-cabin technologies globally,' said Rohan Malhotra, CEO of Roadzen. 'As we scale across the U.S., Europe, and Asia, our focus remains on deploying AI that can reduce accidents, optimize insurance, and unlock the next generation of driver-assist systems.' Nisarg Pandya, Head of DrivebuddyAI commented, 'We've built an AI driver that's been rigorously tested in India-one of the most complex and unpredictable driving environments in the world. Our technology has matured through deployment with logistics fleets that demanded real-world results and ROI-and we delivered it, achieving a 72% reduction in accidents in over 1.8 billion kilometers of real-world driving.' Roadzen's inclusion in the InCabin Market Map Report coincides with increasing global demand for AI-powered driver safety solutions, especially as regulators, insurers, and automakers seek reliable platforms to meet evolving standards in vehicle automation and occupant protection. About Roadzen Inc. Roadzen (NASDAQ:RDZN) is transforming global mobility through its proprietary AI technologies that enable smarter auto insurance, safer driving, and autonomous vehicle innovation. Operating in North America, Europe, and Asia, Roadzen's platforms combine computer vision, telematics, and data science to deliver next-gen mobility solutions for insurers, OEMs, and fleet operators. To learn more, visit Media Contact Monica@


Business Wire
an hour ago
- Business Wire
Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of May 31, 2025
SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News: Median Technologies (Paris:ALMDT): About Median Technologies: Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis®, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit
Yahoo
an hour ago
- Yahoo
Cvent Brings Intelligence and AI to Life Across its Platform with the Launch of CventIQ™
Event software leader promises smarter workflows, higher-return experiences and more SAN ANTONIO, June 10, 2025--(BUSINESS WIRE)--Cvent, an industry-leading meetings, events, and hospitality technology provider, today announced the launch of CventIQ™. CventIQ combines powerful AI capabilities with deep industry expertise, proprietary insights and analytics, a smart platform, and intelligent infrastructure to help marketers, event planners, and hospitality professionals move faster and smarter, collaborate better, and deliver more engaging, high-return experiences. Cvent CEO Reggie Aggarwal unveiled CventIQ during his opening keynote address at Cvent CONNECT this week. Intelligent capabilities to power the modern event economy "CventIQ enhances every aspect of the Cvent platform, and it represents our vision for a more efficient, intelligent, and collaborative future for meetings and events," said Aggarwal. "By infusing advanced AI into the tools our customers already use, we're empowering them to deliver more engaging events, more efficiently, with greater returns. Our launch of CventIQ reflects how we're bringing trustworthy, practical AI to every corner of our platform so our customers can stay ahead of today's fast-evolving landscape while remaining focused on what truly drives impact: human connection." Event organizers, hosts and attendees alike will feel the power of CventIQ. For event planners & marketer, sample benefits include: Instant Session Insights: Instantly analyze audience comments to understand sentiment and gain insight into speaker performance, session content engagement, session logistics, and more. AI-Driven Content Creation: Automatically generate compelling, on-brand content for emails, speaker bios, and event pages to streamline and scale event marketing efforts. Personalization at Scale: Deliver personalized session and networking suggestions to attendees, enhancing engagement and overall satisfaction. For hospitality professionals, sample benefits include: Simplified and Accelerated Prospecting: Streamline outreach with curated planner lists and personalized emails based on hotel account insights, and attract planners with immersive AI-powered 3D room layouts. Faster Responses to Drive Conversion: Accelerate request-for-proposal (RFP) response times with AI-generated proposals, RFP insights and response assistants. Seamless Event Execution: Use intelligent tools, such as smart rooming lists and AI-generated event diagrams, to efficiently manage group business and bring plans to life with precision. For attendees, sample benefits include: Personalized Event Dashboards: Direct access to a personalized event dashboard that organizes every touchpoint, including registration, agenda, contacts, CMP credits, and on-demand content, ensures each attendee has a clear view of their unique event journey at a glance. Effortless Session Snapshots: Real-time AI transcripts and slide captures empower attendees to effortlessly save and revisit important session content with just one tap, ensuring they capture all essential insights without distraction. Efficient Knowledge Transfer: With AI-generated summaries, attendees receive customized highlights and actionable next steps from their event experience, including sessions attended, exhibitor booths visited, and connections made, making it easy to share key takeaways and demonstrate the event's value to colleagues and superiors. CventIQ will continue to evolve with new capabilities designed to meet the dynamic needs of the modern event professional, marketer and hospitality leader. To learn more about CventIQ, visit the website here. About Cvent Cvent is a leading meetings, events, and hospitality technology provider with 5,000+ employees and 24,000+ customers worldwide as of December 31, 2024. Founded in 1999, the company delivers a comprehensive event marketing and management platform and offers a global marketplace where event professionals collaborate with venues to create engaging, impactful experiences. Cvent is headquartered in Tysons, Virginia, just outside of Washington D.C., and has additional offices around the world to support its growing global customer base. The comprehensive Cvent event marketing and management platform offers software solutions to event organizers and marketers for online event registration, venue selection, event marketing and management, virtual and onsite solutions, and attendee engagement. Cvent's suite of products automates and simplifies the event management lifecycle and maximizes the impact of in-person, virtual, and hybrid events. Hotels and venues use Cvent's supplier and venue solutions to win more group and corporate travel business through Cvent's sourcing platforms. Cvent solutions optimize the event management value chain and have enabled clients around the world to manage millions of meetings and events. For more information, please visit View source version on Contacts Media Contact Erica Stoltenberg+1.571.378.6240estoltenberg@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data